US negotiating with Pfizer for millions more doses of COVID-19 vaccine
This illustration picture taken in Paris on November 23, 2020 shows a syringe and a bottle reading "Covid-19 Vaccine" next to the Pfizer company logo. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)
WASHINGTON - The U.S. government is negotiating with Pfizer to acquire tens of millions of additional vaccine doses in exchange for helping the pharmaceutical giant gain better access to manufacturing supplies.
A person with knowledge of the negotiations told The Associated Press on Tuesday that the deal is under discussion but has not been finalized. The person spoke on condition of anonymity to describe ongoing deliberations.
Pfizer's vaccine was the first to gain approval from the Food and Drug Administration and initial shipments went to states last week. It has now been joined by a vaccine from Moderna, which was developed in closer cooperation with scientists from the National Institutes of Health.
A law dating back to the Korean War gives the government authority to direct private companies to produce critical goods in times of national emergency. Called the Defense Production Act, it could be used to help Pfizer secure supplies ranging from needed chemicals to vials to containers and materials to keep its vaccine super-cold. The person who spoke to the AP about the negotiations described using the defense law as an option under consideration.
Moderna's vaccine was developed in close collaboration with the government's own effort, which is called Operation Warp Speed. It was designed to have millions of vaccine doses ready and available to ship once a shot received FDA approval.
Pfizer has a contract to supply the government with 100 million doses of its vaccine under Operation Warp Speed, but government officials have said it's more of an arms-length relationship with the company and they don't have as much visibility into its operations.
Having tens of millions more doses from Pfizer would help the U.S. keep up the pace of vaccinations through the winter and into the spring, moving the nation closer to the goal of vaccinating all Americans.
RELATED: Fauci, CDC say new COVID-19 strain accelerating spread in UK may already be in US
Health and Human Services Secretary Alex Azar said last week that the government was negotiating with Pfizer for more doses, but details provided Tuesday about the company's desire for better access to supplies are new.
Earlier, U.S. officials had said they were discussing the purchase of another 100 million doses of Pfizer vaccine for delivery as early as the middle of next year. Those details and timing may have changed.
Pfizer said in a statement that "we continue to work collaboratively with the U.S. government to get doses of our COVID-19 vaccine to as many Americans as possible. The company is not able to comment on any confidential discussions that may be taking place with the U.S. government."
The vaccine from Pfizer and German pharmaceutical BioNTech immediately raised hopes of taming a pandemic that has killed nearly 320,000 people in the U.S. and hobbled much of the national economy. Health care workers and nursing home residents topped the list as local TV stations across the country began broadcasting scenes of the first vaccinations. Some polls show skepticism about getting vaccinated may be easing.
RELATED: Illinois reports 6,239 coronavirus cases, 116 deaths
After early failures with testing, Trump administration officials are hoping to write a very different ending with vaccines. Operation Warp Speed has financed the development, manufacture and distribution of millions of doses, with the goal of providing a free vaccine to any American who wants one.
Operation Warp Speed is on track to have about 40 million doses of vaccine by the end of this month, of which about 20 million would be allocated for first vaccinations. Distribution of those doses would span into the first week of January. Both the Pfizer and Moderna vaccines require two shots to be fully effective.
The New York Times first reported the new details of negotiations between Pfizer and the Trump administration.